Auxilium and SOBI collaborate on Xiapex

USA-based Auxilium Pharmaceuticals (Nasdaq: AUXL) and Swedish Orphan Biovitrum (STO: SOBI) have entered into a long-term collaboration for the development, supply and commercialization of Xiapex (collagenase clostridium histolyticum), a novel, first-in-class biologic for the treatment of Dupuytren's contracture. In addition, work is on-going to file for approval of Xiapex for the treatment of Peyronie's disease in the European Union.

Under the terms of the collaboration deal, Auxilium will receive significant tiered double-digit royalties based on sales of Xiapex in SOBI’s territories, which will also cover payment for product supply. Additionally, SOBI could make up to $40 million in potential sales milestone payments to Auxilium.

SOBI will receive exclusive rights to commercialize Xiapex for Dupuytren's and Peyronie’s indications, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern and North African countries.